Vanda Pharmaceuticals’ VQW-765 Trial Fails to Meet Primary Endpoint
Vanda said the Phase 3 trial of VQW-765 for anxiety did not meet its primary endpoint, which measured distress during the performance phase of the Trier Social Stress Test in women.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.